Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Mise à jour : Il y a 4 ans
Référence : NCT02030067

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1). The purpose of the Phase 2 portion is to estimate anti-tumor activity in subjects with advanced malignancies (relapsed or refractory pancreatic or advanced bladder cancer).


Critère d'inclusion

  • Solid tumor

Liens